Mars

Last updated January 31, 2026

Innovation Areas

2,578

Inventors

Collaborations

Rankl and btn3a1 immunomodulatory ligands: MarsRecent Research Landscape

Standard immunotherapies fail when tumor cells evade T-cell recognition through low antigen presentation. These innovations engineer specific butyrophilin receptor activation and epigenetic modulation to restore immune visibility.

What technical problems is Mars addressing in Rankl and btn3a1 immunomodulatory ligands?

Insufficient immune system reconstitution

(20)evidences

Short biological half-life and rapid clearance of immunomodulatory agents limit treatment efficacy. Extending functional duration reduces dosing frequency and prevents premature therapeutic degradation.

Insufficient therapeutic tissue specificity

(12)evidences

Therapeutic agents often fail to accumulate at specific pathological sites like bone or cancer cells. Improving localization reduces off-target toxicity and enhances therapeutic efficacy.